AlphaStocks
5.8
Consider Buy

TG Therapeutics, Inc. (TGTX)

As of Sep 20, 2026, TG Therapeutics, Inc. (TGTX) scores 5.8/10 on AlphaStocks' five-model composite, #64 of 168 Health Care stocks. At $57, TGTX trades 27% below its model fair value of $78.

Health Care / Biotechnology

S&P SmallCap 600

$56.92

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#64out of 168 in Health Care

Is TG THERAPEUTICS, INC. a Good Investment in 2026?

TG THERAPEUTICS, INC. (TGTX) scores 5.8 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Lynch model rates TG THERAPEUTICS, INC. as Attractive. However, the Greenblatt Magic Formula model rates it Caution — Earnings yield 1.3% · ROC 13%. TG THERAPEUTICS, INC. currently trades 27% below its estimated fair value of $78. TG THERAPEUTICS, INC. ranks #64 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E20.5ROE24.6Market Cap9B

Estimated Fair Value

$78.0427% below

Trading below estimated fair value. EPS grew 1798% year-over-year. ROE of 25% signals strong profitability. P/E of 21x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Attractive

Growth rate vs price (PEG)

Greenblatt

Caution

Earnings yield 1.3% · ROC 13%

Frequently Asked Questions

Is TG THERAPEUTICS, INC. (TGTX) a good investment?
As of Sep 20, 2026, TG Therapeutics, Inc. (TGTX) scores 5.8/10 on AlphaStocks' five-model composite, #64 of 168 Health Care stocks. At $57, TGTX trades 27% below its model fair value of $78. That is a middle-of-the-pack score with no strong signal either way.
What is TG THERAPEUTICS, INC.'s Piotroski F-Score?
TG THERAPEUTICS, INC.'s Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is TGTX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $78, TGTX appears undervalued. The stock currently trades 27% below its estimated fair value. Trading below estimated fair value. EPS grew 1798% year-over-year. ROE of 25% signals strong profitability. P/E of 21x is moderate for this quality level.
How does TGTX compare to other Health Care stocks?
TG THERAPEUTICS, INC. ranks #64 out of 168 stocks in the Health Care sector, placing it in the top 38% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about TGTX?
AlphaStocks evaluates TGTX using five proven investment models. Piotroski: Neutral; Buffett: Neutral; Graham: Caution; Lynch: Attractive; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 5.8/10.

Similar Stocks

ABBVINCYHRMY

Compare TGTX with

ABBV vs TGTXINCY vs TGTXHRMY vs TGTX

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer